Amarantus Engages BD Biosciences for Development of Alzheimer’s Diagnostic

  Amarantus Engages BD Biosciences for Development of Alzheimer’s Diagnostic

Business Wire

SUNNYVALE, Calif. -- June 13, 2013

Amarantus BioScience Holdings, Inc. (OTCQB: AMBS), a biotechnology company
discovering and developing treatments and diagnostics for diseases associated
with neurodegeneration and apoptosis, today announced it has signed a
laboratory services agreement with BD Biosciences, a segment of BD (Becton,
Dickinson and Company) , a leading global medical technology company, under
which BD’s BD Biosciences Custom Technology Team will perform sample analysis
on Amarantus’ LymPro Test® for Alzheimer’s disease. Financial terms were not
disclosed.

“The LymPro Test is potentially the first available blood test for Alzheimer’s
disease,” said Gerald E. Commissiong, President & CEO of Amarantus. “With this
agreement, we expect to have initial data available in the third quarter of
2013, and now have the capabilities required to place LymPro on a path for
commercialization in 2014.”

Amarantus and BD Biosciences will be focused on verifying the analytical
performance characteristics of LymPro necessary to achieve reproducibility of
the assay. Over time, Amarantus expects to execute multiple clinical studies
and begin worldwide sales of LymPro as the first diagnostic blood test for
Alzheimer’s disease.

About Amarantus

Amarantus is a development-stage biotechnology company founded in January
2008. The Company has a focus on developing certain biologics surrounding the
intellectual property and proprietary technologies it owns to treat and/or
diagnose Parkinson's disease, Traumatic Brain Injury, Ischemic Heart Disease
and other human diseases. The Company owns the intellectual property rights to
a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic
Factor ("MANF") and is developing MANF-based products as treatments for brain
disorders. The Company also is a Founding Member of the Coalition for
Concussion Treatment (#C4CT), a movement initiated in collaboration with
Brewer Sports International seeking to raise awareness of new treatments in
development for concussions and nervous-system disorders. The Company also
owns intellectual property and licenses for the diagnosis of Parkinson's
disease and Alzheimer's disease. For further information please visit
www.Amarantus.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995. Such statements include,
but are not limited to, statements about the possible progress of the MANF
technology in testing for Parkinson’s disease, as well as statements about
expectations, plans and prospects of the development of Amarantus' diagnostic
product candidates for Parkinson’s and Alzheimer’s disease. These
forward-looking statements are subject to a number of risks, uncertainties and
assumptions, including the risks associated with development of therapeutic
drug candidates, as well as the risks, uncertainties and assumptions relating
to the development of Amarantus' new product candidates, including those
identified under "Risk Factors" in Amarantus' most recently filed Annual
Report on Form 10-K and Quarterly Report on Form 10-Q and in other filings
Amarantus periodically makes with the SEC. Actual results may differ
materially from those contemplated by these forward-looking statements
Amarantus does not undertake to update any of these forward-looking statements
to reflect a change in its views or events or circumstances that occur after
the date of this presentation.

Contact:

Investor/Media Contacts
Amarantus
Russell Miller
Director of Investor Relations
310-386-2058
ir@amarantus.com
or
LHA
Don Markley, Senior Vice President
310-691-7100
dmarkley@lhai.com
 
Press spacebar to pause and continue. Press esc to stop.